AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Erectile Dysfunction (ED): Yohimbine is primarily prescribed for the management of erectile dysfunction, particularly in individuals whose ED is resistant to other treatments. It works by blocking alpha-2 adrenergic receptors, which increases blood flow to the penis and enhances erectile function. Yohimbine's mechanism of action differs from that of phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra), making it an alternative option for some patients.
Improved Sexual Performance: Yohimbine may improve sexual performance and libido in some individuals by enhancing sexual arousal and desire. It may be used by men experiencing sexual difficulties related to psychological factors, such as performance anxiety or stress.
Weight Loss Aid: Yohimbine has been marketed as a dietary supplement for weight loss and fat burning. It is believed to promote weight loss by increasing metabolic rate, suppressing appetite, and enhancing the body's ability to burn fat. However, scientific evidence supporting the efficacy of yohimbine for weight loss is limited, and its use for this purpose is controversial.
Stimulant Effects: Yohimbine has stimulant properties due to its ability to increase sympathetic nervous system activity. As a result, it may produce effects such as increased alertness, energy, and heart rate. These stimulant effects may be desirable in certain situations but can also lead to adverse effects such as anxiety, agitation, and insomnia.
Blood Pressure Regulation: Yohimbine can affect blood pressure by dilating blood vessels and increasing peripheral blood flow. In some individuals, particularly those with hypertension or cardiovascular disease, yohimbine may cause fluctuations in blood pressure, including both increases and decreases. Therefore, caution is warranted when using yohimbine in patients with preexisting cardiovascular conditions.
Adverse Effects: Common side effects of yohimbine may include gastrointestinal upset (e.g., nausea, vomiting, diarrhea), headache, dizziness, sweating, and flushing. In some cases, yohimbine may exacerbate anxiety or panic symptoms, especially at higher doses. Serious adverse effects, such as cardiac arrhythmias, myocardial infarction, and hypertensive crisis, have been reported with yohimbine use, particularly when taken in excessive amounts or by individuals with underlying health conditions.
Drug Interactions: Yohimbine may interact with various medications, including antidepressants, antihypertensive drugs, and monoamine oxidase inhibitors (MAOIs), potentially leading to adverse reactions or reduced effectiveness of these medications. Patients should inform their healthcare providers about all medications, supplements, and medical conditions before using yohimbine.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 3.9 | 0.9 | 3.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 1.8 | 1.9 | -0.06 |
| Allergies | 3.3 | 2.3 | 0.43 |
| Allergy to milk products | 1.4 | 0.6 | 1.33 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 3.3 | 4.5 | -0.36 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 0.3 | 4.67 |
| Ankylosing spondylitis | 2.7 | 0.9 | 2 |
| Anorexia Nervosa | 1.2 | 2.3 | -0.92 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 4.3 | 2.4 | 0.79 |
| Atherosclerosis | 1.2 | 1.1 | 0.09 |
| Atrial fibrillation | 2.7 | 0.8 | 2.38 |
| Autism | 5.8 | 5.5 | 0.05 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 1.1 | 1.7 | -0.55 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.6 | 0.3 | 1 |
| Cancer (General) | 0.6 | 2.4 | -3 |
| Carcinoma | 2.7 | 2.2 | 0.23 |
| Celiac Disease | 1.2 | 3.1 | -1.58 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 3.3 | 3.6 | -0.09 |
| Chronic Kidney Disease | 2.7 | 1.4 | 0.93 |
| Chronic Lyme | 0.4 | 0.8 | -1 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 1.7 | -0.89 |
| Chronic Urticaria (Hives) | 0.8 | 0.2 | 3 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 1.3 | -3.33 |
| Cognitive Function | 3 | 1.6 | 0.88 |
| Colorectal Cancer | 3 | 1.6 | 0.88 |
| Constipation | 0.9 | 1 | -0.11 |
| Coronary artery disease | 0.9 | 1.8 | -1 |
| COVID-19 | 6.3 | 7.2 | -0.14 |
| Crohn's Disease | 4.1 | 3.5 | 0.17 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 1.3 | 1.4 | -0.08 |
| Denture Wearers Oral Shifts | 0.7 | 0.7 | |
| Depression | 6.6 | 5.8 | 0.14 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.8 | 1.5 | -0.88 |
| Endometriosis | 1.9 | 2 | -0.05 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 1.4 | 0.7 | 1 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 2.6 | 1.4 | 0.86 |
| Functional constipation / chronic idiopathic constipation | 3.4 | 2.9 | 0.17 |
| gallstone disease (gsd) | 1.5 | 0.8 | 0.88 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 1 | -2.33 |
| Generalized anxiety disorder | 1.3 | 2.5 | -0.92 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 0.8 | 1.63 |
| Graves' disease | 1.5 | 3.3 | -1.2 |
| Gulf War Syndrome | 0.9 | 0.4 | 1.25 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.4 | 0.9 | 1.67 |
| Heart Failure | 2 | 1.3 | 0.54 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.9 | 0.6 | 0.5 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 0.5 | 0.7 | -0.4 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 2.5 | 4.7 | -0.88 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 1.5 | 0.5 | 2 |
| IgA nephropathy (IgAN) | 1.2 | 2.9 | -1.42 |
| Inflammatory Bowel Disease | 5 | 5.5 | -0.1 |
| Insomnia | 1.9 | 2.1 | -0.11 |
| Intelligence | 0.8 | 0.2 | 3 |
| Intracranial aneurysms | 0.7 | 0.9 | -0.29 |
| Irritable Bowel Syndrome | 4.4 | 3.7 | 0.19 |
| ischemic stroke | 2.2 | 0.8 | 1.75 |
| Liver Cirrhosis | 4.9 | 3.1 | 0.58 |
| Long COVID | 4.2 | 5.7 | -0.36 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.6 | 1 | -0.67 |
| Mast Cell Issues / mastitis | 0.3 | 0.9 | -2 |
| ME/CFS with IBS | 0.6 | 1.5 | -1.5 |
| ME/CFS without IBS | 1.3 | 1.3 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.2 | 0.5 | 3.4 |
| Metabolic Syndrome | 4.7 | 5.8 | -0.23 |
| Mood Disorders | 6.6 | 4.8 | 0.38 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 3.7 | 3 | 0.23 |
| Multiple system atrophy (MSA) | 0.7 | 0.7 | 0 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 2.5 | -7.33 |
| Neuropathy (all types) | 0.7 | 1.2 | -0.71 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.6 | 4.1 | 0.12 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 6.4 | 5.3 | 0.21 |
| obsessive-compulsive disorder | 2.6 | 2.4 | 0.08 |
| Osteoarthritis | 1.5 | 1.2 | 0.25 |
| Osteoporosis | 1.9 | 1.3 | 0.46 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 3.9 | 4.3 | -0.1 |
| Polycystic ovary syndrome | 2.8 | 2.3 | 0.22 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 1.2 | 0.8 | 0.5 |
| Primary sclerosing cholangitis | 1.5 | 1.4 | 0.07 |
| Psoriasis | 1.9 | 1.3 | 0.46 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.8 | 3.2 | 0.5 |
| Rosacea | 0.6 | 1 | -0.67 |
| Schizophrenia | 5.1 | 2.6 | 0.96 |
| scoliosis | 0.3 | 0.5 | -0.67 |
| Sjögren syndrome | 1.7 | 2 | -0.18 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.6 | 1.33 |
| Stress / posttraumatic stress disorder | 1.9 | 2.2 | -0.16 |
| Systemic Lupus Erythematosus | 2.1 | 1.8 | 0.17 |
| Tic Disorder | 0.9 | 1.4 | -0.56 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.4 | 3.9 | -0.63 |
| Type 2 Diabetes | 4.6 | 4.7 | -0.02 |
| Ulcerative colitis | 3.6 | 4.2 | -0.17 |
| Unhealthy Ageing | 2.5 | 1.4 | 0.79 |
| Vitiligo | 1.5 | 0.9 | 0.67 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
